A NOVEL RP-HPLC METHOD FOR THE DETECTION AND QUANTIFICATION OF CLARITHROMYCIN OR SPIRAMYCIN IN BULK DRUG SAMPLES AND DOSAGE FORMS

RUNAKO MASLINE KATSIDZIRA, ANITA WESSELS, MARIQUE AUCAMP

Centre of Excellence for Pharmaceutical Sciences, North-West University, Private Bag X6001, Potchefstroom, 2520, South Africa,
Department of Pharmaceutical Chemistry, School of Pharmacy, Faculty of Health Sciences, North-West University, Private Bag X6001, Potchefstroom, 2520, South Africa
Email: Marique.aucamp@nwu.ac.za

Received: 05 Sep 2016 Revised and Accepted: 24 Oct 2016

ABSTRACT

Objective: This study was aimed at developing an HPLC method that would be suitable and sufficiently robust to analyze clarithromycin or spiramycin from bulk materials, amorphous solid dispersions as well as when included into solid dosage forms.

Methods: A C8 column (250 x 4.6 mm, 5 µm) was used as stationary phase, the mobile phase consisted of 0.1 M dipotassium hydrogen orthophosphate buffer (pH 6.0) and acetonitrile in a 50:50 (% v/v) ratio. The flow rate was set to 0.5 ml/min. UV detection of 210 nm was used for clarithromycin and 232 nm for spiramycin. Ambient column and sample tray temperatures were used.

Results: The method proved to be suitable for the detection of both macrolide antibiotics in bulk samples, as part of amorphous solid dispersions as well as in dosage forms. The isocratic elution was rapid. The method was validated in terms of system suitability, limits of detection (LOD), limit of quantification (LOQ), accuracy, precision, linearity, and specificity. This method showed linearity across the concentration range of 4.0-5000.0 µg/ml for both antibiotics.

Conclusion: The developed method showed to be a simple and sufficiently sensitive method for the detection and quantification of either clarithromycin or spiramycin from samples that might contain even very small quantities of the antibiotics.

Keywords: Clarithromycin, Spiramycin, RP-HPLC

Recent studies have shown that opportunistic infections of patients suffering from HIV are the cause of 90% of patient morbidity and mortality [1, 2]. The most prevalent and life-threatening opportunistic infections among people living with HIV in different populations include Mycobacterium tuberculosis, Pneumocystis jirovecii pneumonia, Mycobacterium avium complex (MAC) and Cryptosporidiosis [1, 3]. Azithromycin and clarithromycin are currently the two macrolide antibiotics of choice prescribed for the prophylaxis and treatment of MAC opportunistic infections in HIV patients [4]. Cryptosporidiosis is a life-threatening infection that is very difficult to treat since it causes cholera-like diarrhoea with the profuse daily fluid loss of about 17 liters [5]. Spiramycin is one of the macrolide antibiotics recommended for treating cryptosporidiosis among immunosuppressed individuals [6, 7]. Considering the global dilemma of antimicrobial resistance, there is currently a renewed focus on antibiotics that were not usually the drug of choice for the treatment of certain infections. Spiramycin is one such drug. During our research on clarithromycin and spiramycin, we identified the need for a suitable and single HPLC method that could be used for the identification and analysis of both drugs. Especially, considering that the British Pharmacopoeia (BP) only reports on an HPLC method that is suitable for the analysis of spiramycin from veterinary formulations [8]. No other pharmacopoeia contains an analytical method for spiramycin. Furthermore, the methods included in both the BP and the United States Pharmacopoeia [9] for clarithromycin uses high buffer concentrations, and those methods lead to long HPLC run times.

Clarithromycin is classified as a semi-synthetic antibiotic which forms part of the macrolide group. This antibiotic is derived from erythromycin but differs in the fact that the O-methyl group has been substituted for a hydroxyl group at position six of the lactone ring (fig. 1a) [10]. Spiramycin consists of a 16-membered lactone (platenolide), two amino sugars (D-mycaminose and D-forosamine) and one neutral sugar (L-mycarose) (fig.1b). Spiramycin has three major (I, II, III), three minor components (IV, V, VI) and two other additional spiramycins 18-deoxy-18-dihydrospiramycin (DSPM) and 17-methylenespiramycin. Though spiramycin I is shown to be the main component, the quantity of each component varies according to the manufacturer [11-13].

Fig. 1: Molecular structure of (a) clarithromycin and (b) spiramycin [8]
The objective of this study was to develop an easy, cost-effective but sufficiently robust RP-HPLC method for the detection of clarithromycin or spiramycin. The rationale for this was that the current methods that are available in the literature for both drugs use high concentration buffers as part of the mobile phases and in the instance of clarithromycin, gradient elution is being applied. Therefore, this is a simple method with the ability to accurately detect and quantify both drugs, thereby making it very useful for laboratories that need to analyze both macrolide antibiotics.

Clarithromycin working standard (97.7% purity) and spiramycin (purity of 94.9%, only spiramycin I) were purchased from Sigma-Aldrich (Johannesburg, South Africa) and DB Fine Chemicals (Johannesburg, South Africa). The HPLC grade acetonitrile, potassium dihydrogen orthophosphate, and hydrochloric acid (32%) were purchased from ACE Chemicals (Johannesburg, South Africa). The pharmaceutical dosage form used during specificity testing was Clacee® 250 mg tablets (Aspen Pharmacare, South Africa). In the case of spiramycin, no commercial product was available for purchase and therefore a mixture of typical pharmaceutical excipients was made. This mixture consisted of microcrystalline cellulose, polyvinylpyrrolidone (PVP) K 30, magnesium stearate, talc and croscarmellose sodium. All the excipients used were a kind donation from the Department of Pharmaceutics of the School of Pharmacy, North-West University, and Potchefstroom, South Africa.

A Shimadzu (Kyoto, Japan) UFLC (LC-20AD) chromatographic system, equipped with an SIL-20AC autosampler fitted with a sample cooler, a UV/VIS PDA detector (SPD-M20) and an LC-20AD solvent delivery module was used during the method development and validation. A Phenomenex Luna C8 5 µm, 250 x 4.6 mm column was used as stationary phase. The mobile phase consisted of 0.1 M phosphate buffer (pH adjusted to 6.0 with 0.1 M HCl) and acetonitrile in a ratio of 50/50 %v/v. Isocratic elution was used with a flow rate of 0.5 ml/min. An injection volume of 10 µl was used for the analysis and validation of clarithromycin while an injection volume of 2 µl was found to be suitable for spiramycin. For the detection of clarithromycin, a wavelength of 210 nm was used while spiramycin was detected at 232 nm [9]. For both antibiotics, stock solutions were prepared by separately and accurately weighing 50 mg of drug and diluting it to 1 ml with mobile phase. This resulted in a stock solution of 5000.0 µg/ml for each drug. Aliquots of these stock solutions were then diluted with mobile phase to obtain standard solutions with concentrations ranging from 4.0-5000.0 µg/ml. Each standard solution was filtered using a 0.45 µm PVDF filter into HPLC vials.

During the preparation of product sample for the testing of the specificity of clarithromycin, 10 tablets were weighed and grinded using a mortar and pestle. In the case of spiramycin, a sample was prepared as discussed previously described. For each drug sufficient sample powder was weighed, equivalent to result in a final drug concentration of 1000 µg/ml. Each sample was diluted with mobile phase. The flasks were shaken for 10 min using an ultrasonic shaker. Thereafter each sample was filtered through a 0.45 µm PVDF filter into HPLC vials.

The method was validated as specified by the ICH guideline on the validation of analytical procedures (ICH) [14]. Linearity, range, precision, accuracy, recovery, specificity, limit of detection (LOD) and limit of quantification (LOQ) were the validation parameters. For each drug, eight standard solutions with concentrations over the stated working range were analyzed in duplicate. This was done during two different times by two different analysts. From the obtained data, regression plots of peak area versus drug concentration provided linear regression data as stipulated in table 1.

### Table 1: Validation parameters determined during method validation for the detection and quantification of clarithromycin and spiramycin

<table>
<thead>
<tr>
<th>Validation parameter*</th>
<th>Clarithromycin</th>
<th>Spiramycin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linearity range (µg/ml)</td>
<td>4.0-5000.0</td>
<td>4.0-5000</td>
</tr>
<tr>
<td>Correlation coefficient (r²)</td>
<td>0.9999</td>
<td>0.9999</td>
</tr>
<tr>
<td>Recovery (%) (±RSD)</td>
<td>99.95±1.25%</td>
<td>99.65±1.02%</td>
</tr>
<tr>
<td>LOD (µg/ml) (±RSD)</td>
<td>4.0 (±16.6 %)</td>
<td>1.5 (±12.9%)</td>
</tr>
<tr>
<td>LOQ (µg/ml) (±RSD)</td>
<td>16.0 (±0.36 %)</td>
<td>8.0 (±0.13%)</td>
</tr>
</tbody>
</table>

*The validation parameters were determined from the analysis of eight standard solutions (n = 8) over a concentration range of 4.0–5000.0 µg/ml. %RSD: Percentage relative standard deviation. LOD: Limit of detection, LOQ: Limit of quantification.

The recovery obtained with this method proved to be acceptable for both drugs, due to the fact that the recovery was between the limits of 98.0-102.0%. The determined LOD and LOQ limits for this method also proved to be acceptable with very small concentration levels of both drugs being detectable and quantifiable. The accuracy of the proposed method was tested at clarithromycin concentration levels of 250.0 µg/ml and 1000.0 µg/ml. The recovery for clarithromycin was determined to be between 98.32-101.64%, with a mean recovery of 99.95% and a percentage relative standard deviation (%RSD) of 1.25%. For spiramycin concentration levels of 25.00 µg/ml and 103.00 µg/ml was used for accuracy testing. The results showed recovery between 98.21–101.10%, with a mean recovery of 99.65% (±1.02%). From these results, it can be concluded that the method delivers accurate results. The precision of the method was investigated through determination of repeatability and intermediate precision. The repeatability for both drugs was determined at concentration levels, 200.0, 500.0 and 1025.0 µg/ml, the samples were analyzed in triplicate (table 2).

### Table 2: Summary of repeatability data obtained for clarithromycin and spiramycin

<table>
<thead>
<tr>
<th>Theoretical concentration (µg/ml)</th>
<th>Mean clarithromycin concentration (µg/ml) ±%RSD</th>
<th>Mean spiramycin concentration (µg/ml) ±%RSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>200.0</td>
<td>210.44 (±0.05)</td>
<td>213.43 (±0.50)</td>
</tr>
<tr>
<td>500.0</td>
<td>511.16 (±0.62)</td>
<td>513.88 (±0.18)</td>
</tr>
<tr>
<td>1025.0</td>
<td>1030.45 (±0.04)</td>
<td>1020.73 (±0.28)</td>
</tr>
</tbody>
</table>

*Each reported value is the mean±%RSD of n observations. For repeatability, n is 3. %RSD denotes the percentage standard deviation.

The intermediate precision was measured during three different sampling times. Samples were prepared by different analysts as well and analyzed in duplicate. The resulting data is presented in table 3.

The % RSD for these determinations were not more than 5.0 % and were therefore deemed as sufficient proof of the precision of this method.
The specificity of the method was tested by analyzing the prepared sample solutions which contained typical formulation excipients. Fig. 2 depicts the chromatograms obtained for clarithromycin standard and sample solutions while, fig. 3 depicts the chromatograms obtained for spiramycin standard solution and the sample solution prepared in combination with the mentioned excipients. No peak interference of any of the excipients was observed and therefore the method was deemed suitable for the analysis of formulated dosage forms containing either of the macrolides. The presented results show that the developed method is accurate, precise and specific. A simple HPLC method was developed and validated for the detection and quantification of either clarithromycin or spiramycin. The method proved to be accurate and reproducible and to be suitable for the analysis of either clarithromycin or spiramycin either as bulk drug or when in combination with typical pharmaceutical excipients.

Table 3: Summary of intermediate precision data obtained for both drugs. Samples were analysed on different days, by different analysts.

<table>
<thead>
<tr>
<th>Theoretical concentration (µg/ml)</th>
<th>Mean clarithromycin concentration (µg/ml)±%RSD</th>
<th>Mean spiramycin concentration (µg/ml)±%RSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>1000.0</td>
<td>(1) 999.29 (±1.11%)</td>
<td>(1) 1017.43 (±1.45%)</td>
</tr>
<tr>
<td></td>
<td>(2) 995.53 (±1.19%)</td>
<td>(2) 1018.05 (±0.59%)</td>
</tr>
<tr>
<td></td>
<td>(3) 1018.89 (±0.58%)</td>
<td>(3) 1019.82 (±0.12%)</td>
</tr>
</tbody>
</table>

*Each value is representative of the mean±%RSD of n observations. For the determination of intermediate precision, n is 3. %RSD denotes the percentage standard deviation.

ACKNOWLEDGEMENT

This work was carried out with the financial support of the National Research Foundation of South Africa (NRF) (Grant no. TTK13020718661) and the Centre of Excellence for Pharmaceutical Sciences, (Pharmacen) of the North-West University, Potchefstroom Campus, South Africa.

CONFLICT OF INTERESTS

Declared none

REFERENCES

Aucamp et al.

Int J Pharm Pharm Sci, Vol 8, Issue 12, 310-313


How to cite this article